Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000174776 | SCV000226143 | uncertain significance | not provided | 2014-11-06 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002485128 | SCV002777837 | uncertain significance | Joubert syndrome 7; Meckel syndrome, type 5; COACH syndrome 3 | 2022-04-21 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002516643 | SCV003249902 | uncertain significance | Familial aplasia of the vermis; Meckel-Gruber syndrome | 2021-08-30 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid with glycine at codon 531 of the RPGRIP1L protein (p.Glu531Gly). The glutamic acid residue is highly conserved and there is a moderate physicochemical difference between glutamic acid and glycine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with RPGRIP1L-related conditions. ClinVar contains an entry for this variant (Variation ID: 194412). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Prevention |
RCV004732738 | SCV005348042 | uncertain significance | RPGRIP1L-related disorder | 2024-05-23 | no assertion criteria provided | clinical testing | The RPGRIP1L c.1592A>G variant is predicted to result in the amino acid substitution p.Glu531Gly. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0031% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |